清胰方联合参麦注射液治疗重症急性胰腺炎临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R576

基金项目:


Clinical Study on Qingyi Prescription Combined with Shenmai Injection for Severe Acute Pancreatitis
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察清胰方联合参麦注射液治疗重症急性胰腺炎(SAP) 的临床疗效。方法:选取100 例SAP 患者,按照不同治疗方式分为观察组和对照组,每组50 例。2 组均给予常规治疗,对照组在此基础上给予参麦注射液治疗,观察组在对照组基础上加用清胰方治疗。2 组均治疗2 周。比较2 组临床疗效、症状缓解时间;比较2 组治疗前后血淀粉酶、尿淀粉酶、炎症因子水平及免疫功能。结果:观察组总有效率90.00%,高于对照组78.00% (P<0.05)。观察组腹痛缓解、肠鸣音恢复、首次排便、血淀粉酶恢复时间均短于对照组(P<0.05)。治疗后,2 组血淀粉酶、尿淀粉酶水平均较治疗前降低(P<0.05),观察组血淀粉酶、尿淀粉酶水平均低于对照组(P<0.05)。治疗后,2 组CD4+水平及CD4+/CD8+值均较治疗前升高(P<0.05),CD8+水平均较治疗前降低(P<0.05);观察组CD4+水平及CD4+/CD8+值均高于对照组(P<0.05),CD8+水平低于对照组(P<0.05)。治疗后,2 组超敏C-反应蛋白(hs-CRP)、白细胞介素-2(IL-2)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α) 水平均较治疗前降低(P<0.05),观察组hs-CRP、IL-2、IL-6、TNF-α 水平均低于对照组(P<0.05)。结论:清胰方联合参麦注射液治疗SAP 临床疗效较好,可增强患者的免疫功能,降低炎症因子水平,缓解临床症状。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Qingyi prescription combined with Shenmai injection for severe acute pancreatitis(SAP). Methods: A total of 100 cases of SAP patients were divided into the observation group and the control group according to their different treatment methods,with 50 cases in each group. Both groups were given routine treatment, the control group was additionally treated with Shenmai injection, and the observation group was additionally treated with Qingyi prescription based on the treatment of the control group. Both groups were treated for two weeks. The clinical effects and the remission duration of symptoms in the two groups were compared. Before and after treatment,the levels of blood amylase,urine amylase,inflammatory factors and the indexes of immune function in the two groups were compared. Results:The total effective rate was 90.00% in the observation group,higher than that of 78.00% in the control group(P<0.05). The remission duration of abdominal pain,the recovery time of bowel sounds,the first defecation time and the recovery time of blood amylase in the observation group were shorter than those in the control group(P<0.05). After treatment, the levels of blood amylase and urine amylase in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of blood amylase and urine amylase in the observation group were lower than those in the control group(P<0.05). After treatment,CD4 + levels and CD4 +/CD8 + values in the two groups were increased when compared with those before treatment(P<0.05),and CD8+ levels were decreased(P<0.05);CD4+ level and CD4+/CD8+ value in the observation group were higher than those in the control group(P<0.05),and CD8+ was lower(P<0.05). After treatment, the levels of high- sensitivity C- reactive protein(hs- CRP), interleukin- 2(IL- 2), interleukin- 6(IL- 6) and tumor necrosis factor-α(TNF-α) in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of hs-CRP,IL-2,IL-6 and TNF-α in the observation group were lower than those in the control group(P<0.05). Conclusion: Qingyi prescription combined with Shenmai injection has a good clinical effect in treating SAP, can improve immune function,reduce levels of inflammatory factors and relieve clinical symptoms.

    参考文献
    相似文献
    引证文献
引用本文

李长力,郑喜胜,贾明雅.清胰方联合参麦注射液治疗重症急性胰腺炎临床研究[J].新中医,2022,54(6):106-109

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-03-25
  • 出版日期: